Business and Financial News, In Brief
Amgen hits a snag after a long bull run; an NEJM letter provokes a response from Biogen Idec; AstraZeneca is troubled generics; Europe freezes, and so does a manufacturing facility.
You may also be interested in...
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.